{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:35:30Z","timestamp":1787625330768,"version":"build-2736575974"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There is conflicting evidence concerning the effect of inflammatory bowel disease (IBD) on COVID-19 incidence and outcome. Hence, we aimed to evaluate the published evidence through a systematic review process and perform a meta-analysis to assess the association between IBD and COVID-19. A compressive literature search was performed in PubMed\/Medline, Scopus, Embase, and Cochrane Library from inception to July 2021. A snowball search in Google, Google Scholar, Research Gate, and MedRxiv; and bibliographic research were also performed to identify any other relevant articles. Quantitative observational studies such as cohort, cross-sectional, and case\u2013control studies that assessed the incidence, risk, and outcomes of COVID-19 among the adult IBD patients published in the English language, were considered for this review. The incidence and risk of COVID-19, COVID-19 hospitalization, the severity of COVID-19, and mortality were considered as the outcomes of interest. The Joanna Briggs Institute critical appraisal checklist was used for quality assessment. A subgroup and sensitivity analysis were performed to explore the heterogeneity and robustness of the results, respectively. A total of 86 studies out of 2828 non-duplicate records were considered for this meta-analysis. The studies were single or multicentric internationally from settings such as IBD centres, medical colleges, hospitals, or from the general public. Most of the studies were observed to be of good quality with an acceptable risk of bias. The pooled prevalence of COVID-19, COVID-19 hospitalization, severe COVID-19, and mortality in the IBD population were 6.10%, 10.63%, 40.43%, and 1.94%, respectively. IBD was not significantly (p\u2009&gt;\u20090.05) associated with the risk of COVID-19, COVID-19 hospitalization, severe COVID-19, and mortality. In contrast, ulcerative colitis was significantly associated with a higher risk of COVID-19 (OR 1.37; p\u2009=\u20090.01), COVID-19 hospitalization (OR 1.28; p\u2009&lt;\u20090.00001), and severe COVID-19 (OR 2.45; p\u2009&lt;\u20090.0007). Crohn\u2019s disease was significantly associated with a lesser risk of severe COVID-19 (OR 0.48; p\u2009=\u20090.02). Type of IBD was a potential factor that might have contributed to the higher level of heterogeneity. There was a significant association between ulcerative colitis and increased risk of COVID-19, COVID-19 hospitalization, and severe COVID-19 infection. This association was not observed in patients with Crohns' disease or in those diagnosed non-specifically as IBD.<\/jats:p>","DOI":"10.1038\/s41598-022-25429-2","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T08:07:24Z","timestamp":1670573244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis"],"prefix":"10.1038","volume":"12","author":[{"given":"Maheeba","family":"Abdulla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafeesa","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehad","family":"AlQamish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Mosli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"15","key":"25429_CR1","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1080\/14656566.2020.1792884","volume":"21","author":"S Khan","year":"2020","unstructured":"Khan, S., Gionfriddo, M. R., Cortes-Penfield, N., Thunga, G. & Rashid, M. The trade-off dilemma in pharmacotherapy of COVID-19: Systematic review, meta-analysis, and implications. Expert Opin. Pharmacother. 21(15), 1821\u20131849 (2020).","journal-title":"Expert Opin. Pharmacother."},{"key":"25429_CR2","unstructured":"Worldometer. COVID-19 CORONAVIRUS PANDEMIC: Worldometer; 2021 [updated 31 August 2021. https:\/\/www.worldometers.info\/coronavirus\/. Accessed on 03 September 2021."},{"issue":"1","key":"25429_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s15010-020-01509-1","volume":"49","author":"D Wolff","year":"2021","unstructured":"Wolff, D., Nee, S., Hickey, N. S. & Marschollek, M. J. I. Risk factors for Covid-19 severity and fatality: A structured literature review. Infection 49(1), 15\u201328 (2021).","journal-title":"Infection"},{"key":"25429_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108437","volume":"125","author":"YMT Siahaan","year":"2021","unstructured":"Siahaan, Y. M. T., Ketaren, R. J., Hartoyo, V. & Hariyanto, T. I. Epilepsy and the risk of severe coronavirus disease 2019 outcomes: A systematic review, meta-analysis, and meta-regression. Epilepsy Behav. 125, 108437 (2021).","journal-title":"Epilepsy Behav."},{"key":"25429_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.clnesp.2022.01.016","volume":"48","author":"YMT Siahaan","year":"2022","unstructured":"Siahaan, Y. M. T., Hartoyo, V., Hariyanto, T. I. & Kurniawan, A. Coronavirus disease 2019 (Covid-19) outcomes in patients with sarcopenia: A meta-analysis and meta-regression. Clin. Nutr. ESPEN 48, 158\u2013166 (2022).","journal-title":"Clin. Nutr. ESPEN"},{"key":"25429_CR6","doi-asserted-by":"publisher","DOI":"10.2174\/1573399818666220224123525","author":"M Rashid","year":"2022","unstructured":"Rashid, M., Rajan, A. K., Thunga, G., Shanbhag, V. & Nair, S. Impact of diabetes in COVID-19 associated mucormycosis and its management: A non-systematic literature review. Curr. Diabetes Rev. https:\/\/doi.org\/10.2174\/1573399818666220224123525 (2022).","journal-title":"Curr. Diabetes Rev."},{"key":"25429_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.genhosppsych.2022.01.010","volume":"75","author":"E Pardamean","year":"2022","unstructured":"Pardamean, E., Roan, W., Iskandar, K. T. A., Prayangga, R. & Hariyanto, T. I. Mortality from coronavirus disease 2019 (Covid-19) in patients with schizophrenia: A systematic review, meta-analysis and meta-regression. Gen. Hosp. Psychiatry 75, 61\u201367 (2022).","journal-title":"Gen. Hosp. Psychiatry"},{"issue":"2","key":"25429_CR8","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3906\/sag-2008-91","volume":"51","author":"R Ba\u011fSoyta\u015f","year":"2021","unstructured":"Ba\u011fSoyta\u015f, R. et al. Factors affecting mortality in geriatric patients hospitalized with COVID-19. Turk. J. Med. Sci. 51(2), 454\u2013463 (2021).","journal-title":"Turk. J. Med. Sci."},{"key":"25429_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/JIR.S65979","volume":"7","author":"M Fakhoury","year":"2014","unstructured":"Fakhoury, M., Negrulj, R., Mooranian, A. & Al-Salami, H. Inflammatory bowel disease: Clinical aspects and treatments. J. Inflamm. Res. 7, 113\u2013120 (2014).","journal-title":"J. Inflamm. Res."},{"issue":"1","key":"25429_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","volume":"5","author":"GBD 2017 Inflammatory Bowel Disease Collaborators","year":"2020","unstructured":"GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 5(1), 17\u201330 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"7","key":"25429_CR11","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1136\/gutjnl-2020-321411","volume":"69","author":"C Bezzio","year":"2020","unstructured":"Bezzio, C. et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: An IG-IBD study. Gut 69(7), 1213\u20131217 (2020).","journal-title":"Gut"},{"issue":"11","key":"25429_CR12","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.3390\/jcm10112388","volume":"10","author":"V Belleudi","year":"2021","unstructured":"Belleudi, V. et al. Direct and indirect impact of COVID-19 for patients with immune-mediated inflammatory diseases: A retrospective cohort study. J. Clin. Med. 10(11), 2388 (2021).","journal-title":"J. Clin. Med."},{"issue":"3","key":"25429_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.dld.2020.12.013","volume":"53","author":"G Maconi","year":"2021","unstructured":"Maconi, G. et al. Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population. Dig. Liver Dis. 53(3), 263\u2013270 (2021).","journal-title":"Dig. Liver Dis."},{"key":"25429_CR14","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1111\/jgh.15591","volume":"36","author":"S Ardizzone","year":"2021","unstructured":"Ardizzone, S. et al. Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy. J. Gastroenterol. Hepatol. 36, 3050\u20133055 (2021).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"10","key":"25429_CR15","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.14309\/ajg.0000000000000829","volume":"115","author":"G Fiorino","year":"2020","unstructured":"Fiorino, G. et al. Absence of COVID-19 infection in patients accessing IBD unit at Humanitas, Milan: Implications for postlockdown measures. Am. J. Gastroenterol. 115(10), 1719\u20131721 (2020).","journal-title":"Am. J. Gastroenterol."},{"key":"25429_CR16","doi-asserted-by":"publisher","first-page":"2847316","DOI":"10.1155\/2020\/2847316","volume":"2020","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. The symptoms and medications of patients with inflammatory bowel disease in Hubei Province after COVID-19 epidemic. J. Immunol. Res. 2020, 2847316 (2020).","journal-title":"J. Immunol. Res."},{"issue":"6","key":"25429_CR17","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.dld.2021.03.021","volume":"53","author":"A Viola","year":"2021","unstructured":"Viola, A. et al. Management of patients with inflammatory bowel disease and outcomes during the first wave of the Covid-19 pandemic. Dig. Liver Dis. 53(6), 689\u2013690 (2021).","journal-title":"Dig. Liver Dis."},{"issue":"1","key":"25429_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/jgh.15164","volume":"36","author":"JWY Mak","year":"2021","unstructured":"Mak, J. W. Y., Weng, M. T., Wei, S. C. & Ng, S. C. Zero COVID-19 infection in inflammatory bowel disease patients: Findings from population-based inflammatory bowel disease registries in Hong Kong and Taiwan. J. Gastroenterol. Hepatol. 36(1), 171\u2013173 (2021).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"25429_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ (Clin. Res. Ed). 339, b2535 (2009).","journal-title":"BMJ (Clin. Res. Ed)."},{"issue":"3","key":"25429_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/XEB.0000000000000064","volume":"13","author":"S Moola","year":"2015","unstructured":"Moola, S. et al. Conducting systematic reviews of association (etiology): The Joanna Briggs Institute\u2019s approach. Int. J. Evid. Based Healthc. 13(3), 163\u2013169 (2015).","journal-title":"Int. J. Evid. Based Healthc."},{"key":"25429_CR21","volume-title":"Review Manager 5.3","author":"Centre TNC","year":"2014","unstructured":"Centre TNC. Review Manager 5.3 (The Cochrane Collaboration, 2014)."},{"key":"25429_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JP Higgins","year":"2019","unstructured":"Higgins, J. P. et al. Cochrane Handbook for Systematic Reviews of Interventions (Wiley, 2019)."},{"issue":"2","key":"25429_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2174\/1574884714666190112151202","volume":"14","author":"M Rashid","year":"2019","unstructured":"Rashid, M., Shamshavali, K. & Chhabra, M. Efficacy and safety of nilutamide in patients with metastatic prostate cancer who underwent orchiectomy: A systematic review and metaanalysis. Curr. Clin. Pharmacol. 14(2), 108\u2013115 (2019).","journal-title":"Curr. Clin. Pharmacol."},{"issue":"2","key":"25429_CR24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2174\/1574884715666200513090634","volume":"16","author":"K Mark","year":"2021","unstructured":"Mark, K. et al. Survival benefits of N-acetylcysteine in rodenticide poisoning: Retrospective evidence from an Indian tertiary care setting. Curr. Rev. Clin. Exp. Pharmacol. 16(2), 201\u2013208 (2021).","journal-title":"Curr. Rev. Clin. Exp. Pharmacol."},{"issue":"11","key":"25429_CR25","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.dld.2020.06.007","volume":"52","author":"I Marafini","year":"2020","unstructured":"Marafini, I. et al. Low frequency of COVID-19 in inflammatory bowel diseases. Dig. Liver Dis. 52(11), 1234\u20131235 (2020).","journal-title":"Dig. Liver Dis."},{"issue":"2","key":"25429_CR26","first-page":"151","volume":"113","author":"S IzquierdoSanterv\u00e1s","year":"2021","unstructured":"IzquierdoSanterv\u00e1s, S., Casas Machado, P. & Fern\u00e1ndez, S. L. Influence of the onset of the SARS-CoV-2 pandemic on the diagnosis and treatment of ulcerative colitis. Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva 113(2), 151\u2013152 (2021).","journal-title":"Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva"},{"key":"25429_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102613","volume":"118","author":"M Attauabi","year":"2021","unstructured":"Attauabi, M. et al. Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies\u2014A Danish population-based cohort study. J. Autoimmun. 118, 102613 (2021).","journal-title":"J. Autoimmun."},{"issue":"5","key":"25429_CR28","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1080\/00365521.2021.1901308","volume":"56","author":"KM Moum","year":"2021","unstructured":"Moum, K. M., Moum, B. & Opheim, R. Patients with inflammatory bowel disease on immunosuppressive drugs: Perspectives\u2019 on COVID-19 and health care service during the pandemic. Scand. J. Gastroenterol. 56(5), 545\u2013551 (2021).","journal-title":"Scand. J. Gastroenterol."},{"issue":"2","key":"25429_CR29","first-page":"154","volume":"113","author":"C Su\u00e1rez Ferrer","year":"2021","unstructured":"Su\u00e1rez Ferrer, C., P\u00e9rez Robles, T. & Mart\u00edn-Arranz, M. D. Adherence to intravenous biological treatment in inflammatory bowel disease patients during the COVID-19 pandemic. Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva. 113(2), 154 (2021).","journal-title":"Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva."},{"issue":"11","key":"25429_CR30","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/apt.16349","volume":"53","author":"CA Lamb","year":"2021","unstructured":"Lamb, C. A. et al. Letter: Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study. Aliment. Pharmacol. Ther. 53(11), 1236\u20131240 (2021).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"25429_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/MEG.0000000000002239","volume":"34","author":"V Richter","year":"2022","unstructured":"Richter, V., Bermont, A., Cohen, D. L., Broide, E. & Shirin, H. Effect of inflammatory bowel disease and related medications on COVID-19 incidence, disease severity, and outcome: The Israeli experience. Eur. J. Gastroenterol. Hepatol. 34, 267\u2013273 (2022).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"25429_CR32","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1007\/s10620-021-07040-z","volume":"67","author":"B Caron","year":"2021","unstructured":"Caron, B., Neuville, E. & Peyrin-Biroulet, L. Inflammatory bowel disease and COVID-19 vaccination: A patients\u2019 survey. Dig. Dis. Sci. 67, 2067\u20132073 (2021).","journal-title":"Dig. Dis. Sci."},{"key":"25429_CR33","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.15.21249889","author":"J Sperger","year":"2021","unstructured":"Sperger, J. et al. Development and validation of multivariable prediction models for adverse COVID-19 outcomes in IBD patients. medRxiv. https:\/\/doi.org\/10.1101\/2021.01.15.21249889 (2021).","journal-title":"medRxiv."},{"key":"25429_CR34","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1053\/j.gastro.2021.06.076","volume":"161","author":"A Ben-Tov","year":"2021","unstructured":"Ben-Tov, A. et al. BNT162b2 messenger RNA COVID-19 vaccine effectiveness in patients with inflammatory bowel disease: Preliminary real-world data during mass vaccination campaign. Gastroenterology 161, 1715-1717.e1 (2021).","journal-title":"Gastroenterology"},{"issue":"8","key":"25429_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab048","volume":"27","author":"S Markovic","year":"2021","unstructured":"Markovic, S. et al. The effect of COVID-19 resurgence on morbidity and mortality in patients with IBD on biologic therapy. Inflamm. Bowel Dis. 27(8), e90 (2021).","journal-title":"Inflamm. Bowel Dis."},{"key":"25429_CR36","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.30.21254607","author":"GJ Botwin","year":"2021","unstructured":"Botwin, G. J. et al. Adverse events following SARS-CoV-2 mRNA vaccination among patients with inflammatory bowel disease. medRxiv. https:\/\/doi.org\/10.1101\/2021.03.30.21254607 (2021).","journal-title":"medRxiv."},{"key":"25429_CR37","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1053\/j.gastro.2021.06.012","volume":"161","author":"N Mahmud","year":"2021","unstructured":"Mahmud, N. et al. Risk of venous thromboembolism among patients with inflammatory bowel disease who contract severe acute respiratory syndrome coronavirus 2. Gastroenterology 161, 1709-1711.e1 (2021).","journal-title":"Gastroenterology"},{"issue":"2","key":"25429_CR38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/apt.16410","volume":"54","author":"A Meyer","year":"2021","unstructured":"Meyer, A. et al. Risk of severe COVID-19 in patients treated with IBD medications: A French nationwide study. Aliment. Pharmacol. Ther. 54(2), 160\u2013166 (2021).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"5","key":"25429_CR39","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/ecco-jcc\/jjaa237","volume":"15","author":"R Berte","year":"2021","unstructured":"Berte, R. et al. Seroprevalence of SARS-CoV2 in IBD patients treated with biologic therapy. J. Crohns Colitis 15(5), 864\u2013868 (2021).","journal-title":"J. Crohns Colitis"},{"issue":"4","key":"25429_CR40","doi-asserted-by":"publisher","first-page":"808","DOI":"10.14309\/ajg.0000000000001012","volume":"116","author":"N Khan","year":"2021","unstructured":"Khan, N. et al. Are patients with inflammatory bowel disease at an increased risk of developing SARS-CoV-2 than patients without inflammatory bowel disease? Results from a nationwide veterans\u2019 affairs cohort study. Am. J. Gastroenterol. 116(4), 808\u2013810 (2021).","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"25429_CR41","first-page":"92","volume":"113","author":"P Fern\u00e1ndez \u00c1lvarez","year":"2021","unstructured":"Fern\u00e1ndez \u00c1lvarez, P. et al. Views of patients with inflammatory bowel disease during the COVID-19 pandemic: ACCU survey results. Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva 113(2), 92\u201397 (2021).","journal-title":"Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva"},{"key":"25429_CR42","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s13304-021-01119-y","volume":"73","author":"M Rottoli","year":"2021","unstructured":"Rottoli, M. et al. Inflammatory bowel disease patients requiring surgery can be treated in referral centres regardless of the COVID-19 status of the hospital: Results of a multicentric European study during the first COVID-19 outbreak (COVID-Surg). Updates Surg. 73, 1811\u20131818 (2021).","journal-title":"Updates Surg."},{"key":"25429_CR43","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.gastrohep.2021.03.012","volume":"45","author":"E Refaie","year":"2022","unstructured":"Refaie, E. et al. Impact of the lockdown period due to the COVID-19 pandemic in patients with inflammatory bowel disease. Gastroenterol. Hepatol. 45, 114\u2013122 (2022).","journal-title":"Gastroenterol. Hepatol."},{"issue":"1","key":"25429_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2021.1926840","volume":"13","author":"RC Newsome","year":"2021","unstructured":"Newsome, R. C. et al. The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort. Gut Microbes 13(1), 1\u201315 (2021).","journal-title":"Gut Microbes"},{"issue":"7","key":"25429_CR45","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.gastrohep.2020.11.018","volume":"44","author":"E Navarro-Correal","year":"2021","unstructured":"Navarro-Correal, E. et al. Impact of the COVID-19 pandemic on the activity of advanced-practice nurses on a reference unit for inflammatory bowel disease. Gastroenterol. Hepatol. 44(7), 481\u2013488 (2021).","journal-title":"Gastroenterol. Hepatol."},{"issue":"3","key":"25429_CR46","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1053\/j.gastro.2020.05.009","volume":"159","author":"J Gubatan","year":"2020","unstructured":"Gubatan, J. et al. SARS-CoV-2 testing, prevalence, and predictors of COVID-19 in patients with inflammatory bowel disease in Northern California. Gastroenterology 159(3), 1141\u20134.e2 (2020).","journal-title":"Gastroenterology"},{"issue":"2","key":"25429_CR47","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1053\/j.gastro.2020.04.043","volume":"159","author":"I Rodr\u00edguez-Lago","year":"2020","unstructured":"Rodr\u00edguez-Lago, I. et al. Characteristics and prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque Country (Spain). Gastroenterology 159(2), 781\u2013783 (2020).","journal-title":"Gastroenterology"},{"issue":"2","key":"25429_CR48","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2020.05.032","volume":"159","author":"EJ Brenner","year":"2020","unstructured":"Brenner, E. J. et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: Results from an international registry. Gastroenterology 159(2), 481\u201391.e3 (2020).","journal-title":"Gastroenterology"},{"issue":"9","key":"25429_CR49","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.cgh.2020.04.071","volume":"18","author":"M Allocca","year":"2020","unstructured":"Allocca, M. et al. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts. Clin. Gastroenterol. Hepatol. 18(9), 2134\u20132135 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"7","key":"25429_CR50","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1177\/2050640620929133","volume":"8","author":"F Scaldaferri","year":"2020","unstructured":"Scaldaferri, F. et al. Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre. United Eur. Gastroenterol. J. 8(7), 775\u2013781 (2020).","journal-title":"United Eur. Gastroenterol. J."},{"issue":"2","key":"25429_CR51","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/apt.15804","volume":"52","author":"C Taxonera","year":"2020","unstructured":"Taxonera, C. et al. 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. Aliment. Pharmacol. Ther. 52(2), 276\u2013283 (2020).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"25429_CR52","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.gastrohep.2020.11.002","volume":"45","author":"R Quera","year":"2022","unstructured":"Quera, R. et al. Impact of COVID-19 on a cohort of patients with inflammatory bowel disease at a specialised centre in Chile. Gastroenterol. Hepatol. 45, 110\u2013112 (2022).","journal-title":"Gastroenterol. Hepatol."},{"issue":"4","key":"25429_CR53","doi-asserted-by":"publisher","first-page":"549","DOI":"10.15403\/jgld-3183","volume":"29","author":"R Vadan","year":"2020","unstructured":"Vadan, R. et al. Inflammatory bowel disease management in a Romanian tertiary gastroenterology center: Challenges of the COVID-19 pandemic. J. Gastrointest. Liver Dis. JGLD 29(4), 549\u2013553 (2020).","journal-title":"J. Gastrointest. Liver Dis. JGLD"},{"issue":"4","key":"25429_CR54","first-page":"238","volume":"12","author":"A Anushiravani","year":"2020","unstructured":"Anushiravani, A. et al. A Supporting system for management of patients with inflammatory bowel disease during COVID-19 outbreak: Iranian experience-study protocol. Middle East J. Dig. Dis. 12(4), 238\u2013245 (2020).","journal-title":"Middle East J. Dig. Dis."},{"key":"25429_CR55","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1093\/ecco-jcc\/jjaa154","volume":"14","author":"M Fumery","year":"2020","unstructured":"Fumery, M., Matias, C. & Brochot, E. Seroconversion of immunoglobulins to SARS-CoV2 in patients with inflammatory bowel disease patients treated by biologics. J. Crohn\u2019s Colitis 14, 1792\u20131793 (2020).","journal-title":"J. Crohn's Colitis"},{"issue":"7","key":"25429_CR56","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1093\/ibd\/izab041","volume":"27","author":"F Xu","year":"2021","unstructured":"Xu, F., Carlson, S. A., Wheaton, A. G. & Greenlund, K. J. COVID-19 hospitalizations among U.S. Medicare beneficiaries with inflammatory bowel disease, April 1 to July 31, 2020. Inflamm. Bowel Dis. 27(7), 1166\u20131169 (2021).","journal-title":"Inflamm. Bowel Dis."},{"key":"25429_CR57","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1111\/jgh.15588","volume":"36","author":"NSF Queiroz","year":"2021","unstructured":"Queiroz, N. S. F. et al. COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry. J. Gastroenterol. Hepatol. 36, 3033\u20133040 (2021).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"25429_CR58","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1053\/j.gastro.2021.06.014","volume":"161","author":"YB Hadi","year":"2021","unstructured":"Hadi, Y. B. et al. COVID-19 vaccination is safe and effective in patients with inflammatory bowel disease: Analysis of a large multi-institutional research network in the United States. Gastroenterology 161, 1336-1339.e3 (2021).","journal-title":"Gastroenterology"},{"key":"25429_CR59","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1093\/ibd\/izab133","volume":"27","author":"F Crispino","year":"2021","unstructured":"Crispino, F., Brinch, D., Carrozza, L. & Cappello, M. Acceptance of SARS-CoV-2 vaccination among a cohort of IBD patients from southern Italy: A cross-sectional survey. Inflamm. Bowel Dis. 27, e134\u2013e135 (2021).","journal-title":"Inflamm. Bowel Dis."},{"key":"25429_CR60","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1016\/j.cgh.2021.05.060","volume":"19","author":"M Agrawal","year":"2021","unstructured":"Agrawal, M. et al. COVID-19 outcomes among racial and ethnic minority individuals with inflammatory bowel disease in the United States. Clin. Gastroenterol. Hepatol. 19, 2210-2213.e3 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"25429_CR61","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/jgh3.12551","volume":"5","author":"SR Askar","year":"2021","unstructured":"Askar, S. R. et al. Egypt\u2019s second wave of coronavirus disease of 2019 pandemic and its impact on patients with inflammatory bowel disease. JGH Open 5(6), 664\u2013668 (2021).","journal-title":"JGH Open"},{"key":"25429_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102632","volume":"120","author":"J Kjeldsen","year":"2021","unstructured":"Kjeldsen, J. et al. Outcome of COVID-19 in hospitalized patients with chronic inflammatory diseases. A population based national register study in Denmark. J. Autoimmun. 120, 102632 (2021).","journal-title":"J. Autoimmun."},{"issue":"7","key":"25429_CR63","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1053\/j.gastro.2021.02.029","volume":"160","author":"H Khalili","year":"2021","unstructured":"Khalili, H. et al. Association between collagenous and lymphocytic colitis and risk of severe coronavirus disease 2019. Gastroenterology 160(7), 2585\u20137.e3 (2021).","journal-title":"Gastroenterology"},{"issue":"6","key":"25429_CR64","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/ibd\/izaa223","volume":"27","author":"C Taxonera","year":"2021","unstructured":"Taxonera, C. et al. Innovation in IBD care during the COVID-19 pandemic: Results of a cross-sectional survey on patient-reported experience measures. Inflamm. Bowel Dis. 27(6), 864\u2013869 (2021).","journal-title":"Inflamm. Bowel Dis."},{"issue":"5","key":"25429_CR65","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/ecco-jcc\/jjaa243","volume":"15","author":"M Agrawal","year":"2021","unstructured":"Agrawal, M. et al. Physician practice patterns in holding inflammatory bowel disease medications due to COVID-19, in the SECURE-IBD Registry. J. Crohns Colitis 15(5), 860\u2013863 (2021).","journal-title":"J. Crohns Colitis"},{"issue":"5","key":"25429_CR66","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/jgh3.12498","volume":"5","author":"UC Ghoshal","year":"2021","unstructured":"Ghoshal, U. C. et al. Care of inflammatory bowel disease patients during coronavirus disease-19 pandemic using digital health-care technology. JGH Open 5(5), 535\u2013541 (2021).","journal-title":"JGH Open"},{"issue":"5","key":"25429_CR67","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1093\/ibd\/izaa162","volume":"27","author":"JE Axelrad","year":"2021","unstructured":"Axelrad, J. E. et al. From the American Epicenter: Coronavirus disease 2019 in patients with inflammatory bowel disease in the New York City metropolitan area. Inflamm. Bowel Dis. 27(5), 662\u2013666 (2021).","journal-title":"Inflamm. Bowel Dis."},{"issue":"5","key":"25429_CR68","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/gutjnl-2021-324388","volume":"70","author":"NA Kennedy","year":"2021","unstructured":"Kennedy, N. A. et al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut 70(5), 865\u2013875 (2021).","journal-title":"Gut"},{"issue":"6","key":"25429_CR69","doi-asserted-by":"publisher","first-page":"S-146","DOI":"10.1016\/S0016-5085(21)01104-5","volume":"160","author":"J Dailey","year":"2021","unstructured":"Dailey, J. et al. 731 Failure to develop neutralizing antibodies following SARS-COV-2 infection in young patients with inflammatory bowel disease receiving biologics. Gastroenterology 160(6), S-146 (2021).","journal-title":"Gastroenterology"},{"key":"25429_CR70","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1093\/ecco-jcc\/jjab071","volume":"15","author":"M Agrawal","year":"2021","unstructured":"Agrawal, M. et al. The impact of vedolizumab on COVID-19 outcomes among adult IBD patients in the SECURE-IBD registry. J. Crohn\u2019s Colitis 15, 1877\u20131884 (2021).","journal-title":"J. Crohn's Colitis"},{"issue":"4","key":"25429_CR71","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/ibd\/izaa303","volume":"27","author":"M Agrawal","year":"2021","unstructured":"Agrawal, M. et al. Characteristics and outcomes of IBD patients with COVID-19 on tofacitinib therapy in the SECURE-IBD Registry. Inflamm. Bowel Dis. 27(4), 585\u2013589 (2021).","journal-title":"Inflamm. Bowel Dis."},{"issue":"4","key":"25429_CR72","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/ecco-jcc\/jjaa215","volume":"15","author":"L Derikx","year":"2021","unstructured":"Derikx, L. et al. Clinical outcomes of Covid-19 in patients with inflammatory bowel disease: A nationwide cohort study. J. Crohns Colitis 15(4), 529\u2013539 (2021).","journal-title":"J. Crohns Colitis"},{"issue":"4","key":"25429_CR73","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/ecco-jcc\/jjaa205","volume":"15","author":"M Attauabi","year":"2021","unstructured":"Attauabi, M. et al. Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease\u2014A Danish prospective population-based cohort study. J. Crohns Colitis 15(4), 540\u2013550 (2021).","journal-title":"J. Crohns Colitis"},{"issue":"4","key":"25429_CR74","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/gutjnl-2020-322539","volume":"70","author":"RC Ungaro","year":"2021","unstructured":"Ungaro, R. C. et al. Effect of IBD medications on COVID-19 outcomes: Results from an international registry. Gut 70(4), 725\u2013732 (2021).","journal-title":"Gut"},{"issue":"3","key":"25429_CR75","first-page":"226","volume":"131","author":"M \u0141odyga","year":"2021","unstructured":"\u0141odyga, M. et al. Inflammatory bowel disease is associated with higher seroprevalence rates of antibodies against SARS-CoV-2. Pol. Arch. Intern. Med. 131(3), 226\u2013232 (2021).","journal-title":"Pol. Arch. Intern. Med."},{"issue":"3","key":"25429_CR76","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.dld.2020.12.012","volume":"53","author":"F Rizzello","year":"2021","unstructured":"Rizzello, F. et al. COVID-19 in IBD: The experience of a single tertiary IBD center. Dig. Liver Dis. 53(3), 271\u2013276 (2021).","journal-title":"Dig. Liver Dis."},{"issue":"2","key":"25429_CR77","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ueg2.12049","volume":"9","author":"JF Ludvigsson","year":"2021","unstructured":"Ludvigsson, J. F. et al. Inflammatory bowel disease and risk of severe COVID-19: A nationwide population-based cohort study in Sweden. United Eur. Gastroenterol. J. 9(2), 177\u2013192 (2021).","journal-title":"United Eur. Gastroenterol. J."},{"key":"25429_CR78","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1097\/MCG.0000000000001504","volume":"56","author":"F Schlabitz","year":"2022","unstructured":"Schlabitz, F. et al. Inflammatory bowel disease and COVID-19: How have patients coped so far?. J. Clin. Gastroenterol. 56, e126\u2013e130 (2022).","journal-title":"J. Clin. Gastroenterol."},{"issue":"2","key":"25429_CR79","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/ibd\/izaa278","volume":"27","author":"KE Burke","year":"2021","unstructured":"Burke, K. E. et al. Immunosuppressive therapy and risk of COVID-19 infection in patients with inflammatory bowel diseases. Inflamm. Bowel Dis. 27(2), 155\u2013161 (2021).","journal-title":"Inflamm. Bowel Dis."},{"key":"25429_CR80","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1007\/s10620-020-06807-0","volume":"66","author":"I Iborra","year":"2021","unstructured":"Iborra, I. et al. Treatment adherence and clinical outcomes of patients with inflammatory bowel disease on biological agents during the SARS-CoV-2 pandemic. Dig. Dis. Sci. 66, 4191\u20134196 (2021).","journal-title":"Dig. Dis. Sci."},{"issue":"2","key":"25429_CR81","first-page":"98","volume":"113","author":"I El Hajra","year":"2021","unstructured":"El Hajra, I. et al. Consequences and management of COVID-19 on the care activity of an Inflammatory Bowel Disease Unit. Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva 113(2), 98\u2013102 (2021).","journal-title":"Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva"},{"issue":"1","key":"25429_CR82","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/ibd\/izaa221","volume":"27","author":"I Guerra","year":"2021","unstructured":"Guerra, I. et al. Incidence, clinical characteristics, and evolution of SARS-CoV-2 infection in patients with inflammatory bowel disease: A single-center study in Madrid, Spain. Inflamm. Bowel Dis. 27(1), 25\u201333 (2021).","journal-title":"Inflamm. Bowel Dis."},{"issue":"1","key":"25429_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237202","volume":"16","author":"V Orlando","year":"2021","unstructured":"Orlando, V. et al. Development and validation of a clinical risk score to predict the risk of SARS-CoV-2 infection from administrative data: A population-based cohort study from Italy. PLoS\u00a0One 16(1), e0237202 (2021).","journal-title":"PLoS\u00a0One"},{"issue":"5","key":"25429_CR84","first-page":"2418","volume":"25","author":"L Scucchi","year":"2021","unstructured":"Scucchi, L. et al. Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease. Eur. Rev. Med. Pharmacol. Sci. 25(5), 2418\u20132424 (2021).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"6","key":"25429_CR85","first-page":"2744","volume":"25","author":"S Carparelli","year":"2021","unstructured":"Carparelli, S. et al. Worse impact of second wave COVID-19 pandemic in adults but not in children with inflammatory bowel disease: An Italian single tertiary center experience. Eur. Rev. Med. Pharmacol. Sci. 25(6), 2744\u20132747 (2021).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"8","key":"25429_CR86","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1007\/s40520-021-01917-9","volume":"33","author":"M Calafat","year":"2021","unstructured":"Calafat, M. et al. Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease. Aging Clin. Exp. Res. 33(8), 2355\u20132359 (2021).","journal-title":"Aging Clin. Exp. Res."},{"key":"25429_CR87","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s10620-021-07104-0","volume":"67","author":"R Parekh","year":"2022","unstructured":"Parekh, R. et al. Presence of comorbidities associated with severe coronavirus infection in patients with inflammatory bowel disease. Dig. Dis. Sci. 67, 1271\u20131277 (2022).","journal-title":"Dig. Dis. Sci."},{"issue":"8","key":"25429_CR88","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.cgh.2021.02.004","volume":"19","author":"RS Dalal","year":"2021","unstructured":"Dalal, R. S. et al. COVID-19 vaccination intent and perceptions among patients with inflammatory bowel diseases. Clin. Gastroenterol. Hepatol. 19(8), 1730\u20132.e2 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"3","key":"25429_CR89","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2021.05.044","volume":"161","author":"N Khan","year":"2021","unstructured":"Khan, N. & Mahmud, N. Effectiveness of SARS-CoV-2 vaccination in a veterans affairs cohort of patients with inflammatory bowel disease with diverse exposure to immunosuppressive medications. Gastroenterology 161(3), 827\u2013836 (2021).","journal-title":"Gastroenterology"},{"issue":"9","key":"25429_CR90","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1136\/gutjnl-2021-324356","volume":"70","author":"N Khan","year":"2021","unstructured":"Khan, N., Mahmud, N., Trivedi, C., Reinisch, W. & Lewis, J. D. Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System. Gut 70(9), 1657\u20131664 (2021).","journal-title":"Gut"},{"issue":"3","key":"25429_CR91","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1053\/j.gastro.2021.01.170","volume":"160","author":"R Opheim","year":"2021","unstructured":"Opheim, R., Moum, K. & Moum, B. Patients with inflammatory bowel disease perspective on COVID-19 and health care service during the pandemic. Gastroenterology 160(3), S69 (2021).","journal-title":"Gastroenterology"},{"issue":"6","key":"25429_CR92","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1053\/j.gastro.2020.08.046","volume":"159","author":"L Norsa","year":"2020","unstructured":"Norsa, L. et al. Asymptomatic severe acute respiratory syndrome coronavirus 2 infection in patients with inflammatory bowel disease under biologic treatment. Gastroenterology 159(6), 2229\u201331.e2 (2020).","journal-title":"Gastroenterology"},{"issue":"1","key":"25429_CR93","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2020-000541","volume":"7","author":"RJ Harris","year":"2020","unstructured":"Harris, R. J. et al. Life in lockdown: Experiences of patients with IBD during COVID-19. BMJ Open Gastroenterol. 7(1), e000541 (2020).","journal-title":"BMJ Open Gastroenterol."},{"issue":"11","key":"25429_CR94","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.3390\/jcm9113533","volume":"9","author":"M Allocca","year":"2020","unstructured":"Allocca, M. et al. Patients with inflammatory bowel disease are not at increased risk of COVID-19: A large multinational cohort study. J. Clin. Med. 9(11), 3533 (2020).","journal-title":"J. Clin. Med."},{"issue":"11","key":"25429_CR95","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1093\/ibd\/izaa254","volume":"26","author":"MC Fantini","year":"2020","unstructured":"Fantini, M. C. et al. Telemedicine and remote screening for COVID-19 in inflammatory bowel disease patients: Results from the SoCOVID-19 survey. Inflamm. Bowel Dis. 26(11), e134\u2013e136 (2020).","journal-title":"Inflamm. Bowel Dis."},{"issue":"11","key":"25429_CR96","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1093\/ibd\/izaa244","volume":"26","author":"C Vigan\u00f2","year":"2020","unstructured":"Vigan\u00f2, C. et al. COVID-19 in patients with inflammatory bowel disease: A single-center observational study in Northern Italy. Inflamm. Bowel Dis. 26(11), e138\u2013e139 (2020).","journal-title":"Inflamm. Bowel Dis."},{"key":"25429_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105061","volume":"160","author":"M Allocca","year":"2020","unstructured":"Allocca, M. et al. Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan. Pharmacol. Res. 160, 105061 (2020).","journal-title":"Pharmacol. Res."},{"issue":"4","key":"25429_CR98","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1053\/j.gastro.2020.05.066","volume":"159","author":"DJ Lukin","year":"2020","unstructured":"Lukin, D. J. et al. Baseline disease activity and steroid therapy stratify risk of COVID-19 in patients with inflammatory bowel disease. Gastroenterology 159(4), 1541\u20134.e2 (2020).","journal-title":"Gastroenterology"},{"issue":"4","key":"25429_CR99","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1053\/j.gastro.2020.06.003","volume":"159","author":"S Singh","year":"2020","unstructured":"Singh, S. et al. Risk of severe coronavirus disease 2019 in patients with inflammatory bowel disease in the United States: A multicenter research network study. Gastroenterology 159(4), 1575\u20138.e4 (2020).","journal-title":"Gastroenterology"},{"issue":"10","key":"25429_CR100","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1093\/ibd\/izaa242","volume":"26","author":"C Bezzio","year":"2020","unstructured":"Bezzio, C. et al. Biologic therapies may reduce the risk of COVID-19 in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 26(10), e107\u2013e109 (2020).","journal-title":"Inflamm. Bowel Dis."},{"key":"25429_CR101","doi-asserted-by":"publisher","first-page":"S360","DOI":"10.14309\/01.ajg.0000704916.59012.8d","volume":"115","author":"S Hong","year":"2020","unstructured":"Hong, S. et al. S0717 Inflammatory bowel disease is not associated with severe outcomes of COVID-19: A cohort study from the United States epicenter. Off. J. Am. Coll. Gastroenterol. 115, S360 (2020).","journal-title":"Off. J. Am. Coll. Gastroenterol."},{"key":"25429_CR102","doi-asserted-by":"publisher","first-page":"S365","DOI":"10.14309\/01.ajg.0000704956.98146.28","volume":"115","author":"E Lewine","year":"2020","unstructured":"Lewine, E., Trieu, J., Asamoah, N., Venu, M. & Naik, A. S0727 COVID-19 impact on IBD patients in a tertiary care IBD program. Off. J. Am. Coll. Gastroenterol. 115, S365 (2020).","journal-title":"Off. J. Am. Coll. Gastroenterol."},{"issue":"5","key":"25429_CR103","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4103\/sjg.SJG_220_20","volume":"26","author":"M Mosli","year":"2020","unstructured":"Mosli, M. et al. A cross-sectional survey on the psychological impact of the COVID-19 pandemic on inflammatory bowel disease patients in Saudi Arabia. Saudi J. Gastroenterol. 26(5), 263\u2013271 (2020).","journal-title":"Saudi J. Gastroenterol."},{"key":"25429_CR104","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.imlet.2020.05.002","volume":"224","author":"A Hormati","year":"2020","unstructured":"Hormati, A. et al. Are there any association between COVID-19 severity and immunosuppressive therapy?. Immunol. Lett. 224, 12\u201313 (2020).","journal-title":"Immunol. Lett."},{"key":"25429_CR105","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1093\/ecco-jcc\/jjaa126","volume":"14","author":"PC Grunert","year":"2020","unstructured":"Grunert, P. C., Reuken, P. A., Stallhofer, J., Teich, N. & Stallmach, A. Inflammatory bowel disease in the COVID-19 pandemic\u2014The patients\u2019 perspective. J. Crohn\u2019s Colitis 14, 1702\u20131708 (2020).","journal-title":"J. Crohn's Colitis"},{"issue":"6","key":"25429_CR106","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S2468-1253(20)30121-7","volume":"5","author":"P An","year":"2020","unstructured":"An, P. et al. Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China. Lancet Gastroenterol. Hepatol. 5(6), 525\u2013527 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"2","key":"25429_CR107","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/2050640620972602","volume":"9","author":"AK Singh","year":"2021","unstructured":"Singh, A. K., Jena, A., Kumar, M. P., Sharma, V. & Sebastian, S. Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta-analysis. United Eur. Gastroenterol. J. 9(2), 159\u2013176 (2021).","journal-title":"United Eur. Gastroenterol. J."},{"key":"25429_CR108","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1093\/ibd\/izab236","volume":"28","author":"K Tripathi","year":"2022","unstructured":"Tripathi, K. et al. COVID-19 and outcomes in patients with inflammatory bowel disease: Systematic review and meta-analysis. Inflamm. Bowel Dis. 28, 1265\u20131279 (2022).","journal-title":"Inflamm. Bowel Dis."},{"issue":"1","key":"25429_CR109","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2021-000774","volume":"8","author":"F Alrashed","year":"2021","unstructured":"Alrashed, F., Battat, R., Abdullah, I., Charabaty, A. & Shehab, M. Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: A systematic review and meta-analysis. BMJ Open Gastroenterol. 8(1), e000774 (2021).","journal-title":"BMJ Open Gastroenterol."},{"issue":"4","key":"25429_CR110","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/jgh3.12728","volume":"6","author":"F Alrashed","year":"2022","unstructured":"Alrashed, F., Alasfour, H. & Shehab, M. Impact of biologics and small molecules for inflammatory bowel disease on COVID-19-related hospitalization and mortality: A systematic review and meta-analysis. JGH Open 6(4), 241\u2013250 (2022).","journal-title":"JGH Open"},{"issue":"11","key":"25429_CR111","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1111\/jgh.15191","volume":"35","author":"MH Lee","year":"2020","unstructured":"Lee, M. H. et al. Incidence of SARS-CoV-2 infection in inflammatory bowel disease. J. Gastroenterol. Hepatol. 35(11), 2021\u20132022 (2020).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"12","key":"25429_CR112","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.cgh.2012.07.006","volume":"10","author":"S Pola","year":"2012","unstructured":"Pola, S. et al. Strategies for the care of adults hospitalized for active ulcerative colitis. Clin. Gastroenterol. Hepatol. 10(12), 1315\u201325.e4 (2012).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"25429_CR113","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14645","volume":"75","author":"M Rashid","year":"2021","unstructured":"Rashid, M. et al. Efficacy and safety of corticosteroids in acute respiratory distress syndrome: An overview of meta-analyses. Int. J. Clin. Pract. 75, e14645 (2021).","journal-title":"Int. J. Clin. Pract."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25429-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25429-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25429-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T14:05:28Z","timestamp":1701525928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25429-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":113,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["25429"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-25429-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,9]]},"assertion":[{"value":"9 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21333"}}